We executed a non-exclusive license agreement with StemoniX, Inc. which provides a service of iPS cell-derived cells for research use, on the basic and improvement patents which we have been granted a sublicensing right from Kyoto University and from Osaka University respectively.
We just opened a search window on the page of Patent Portfolio for keyword retrieval. It has been made available to search our patent portfolio not only by category, but also by various keywords depending on the descriptions in bibliographic data pages (application No., publication No., inventor, applicant (assignee), title of invention, abstract, etc.), and it would be helpful for you to find available technologies from more than 100 patent families from our Patent Portfolio which is frequently updated. Please try it out and find the one you are looking for.
A business plan of iPS Academia Japan, Inc. for iPS cell technology transfer operations (TLO operations) has been authorized by both the Minister of Education, Culture, Sports, Science and Technology (MEXT) and the Minister of Economy, Trade and Industry (METI) under the TLO Law (Law No. 52, May 6, 1998) in Japan, and then we have become an approved TLO in January 22, 2016.
Our office will be closed for winter holidays from Tuesday 29th December 2015 to Sunday 3rd January 2016.
Please understand that our earliest replay to any inquiries received during the above period will be made on or after Monday 4th January 2016.
We apologize for your inconvenience this may cause you during this period.
We executed a non-exclusive license agreement with Applied StemCell, Inc. which provides iPS cell derived cells and services for iPS cell generation, differentiation and gene modification for research use, on the patents related to iPS cells technology which we have been granted a sublicensing right from Kyoto University.
We presented our exhibition in Japan Pavilion hosted by JETRO at “BIO-Europe2015” in Munich, Germany from November 2nd (Mon.) till November 4th (Fri.), 2015. We very much appreciate many meetings in Munich regarding our possible collaborations.
We executed a license agreement with Cartilize Incorporated which provides iPS cell-derived chondrocyte products for use in therapeutic applications and research purposes, the license allowing exclusive and non-exclusive rights, respectively, on the patents related to chondrocyte induction and those related to iPS cell technology, for all of which we have been granted a sublicensing right from Kyoto University.
We very much appreciate your visits to our booth at “BioJapan2015” in Yokohama from October 14th (Wed) till October 16th (Fri), 2015. The exhibition was successfully finished.
We executed a non-exclusive license agreement with Regenerative Medical Solutions which provides pancreatic cell products for research use, on the patents related to iPS cell technology which we have been granted a sublicensing right from Kyoto University.
A non-exclusive license with a sublicensing right has been granted from ETPL, a leading TLO in Singapore, on 3 families of patents and patent applications of A*STAR relating to marked acceleration of iPSC generation (AJ129, 130, 131).